These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

586 related articles for article (PubMed ID: 10421617)

  • 1. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction.
    Kumar GN; Dykstra J; Roberts EM; Jayanti VK; Hickman D; Uchic J; Yao Y; Surber B; Thomas S; Granneman GR
    Drug Metab Dispos; 1999 Aug; 27(8):902-8. PubMed ID: 10421617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes.
    Kumar GN; Rodrigues AD; Buko AM; Denissen JF
    J Pharmacol Exp Ther; 1996 Apr; 277(1):423-31. PubMed ID: 8613951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A.
    Ma B; Prueksaritanont T; Lin JH
    Drug Metab Dispos; 2000 Feb; 28(2):125-30. PubMed ID: 10640508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alprazolam-ritonavir interaction: implications for product labeling.
    Greenblatt DJ; von Moltke LL; Harmatz JS; Durol AL; Daily JP; Graf JA; Mertzanis P; Hoffman JL; Shader RI
    Clin Pharmacol Ther; 2000 Apr; 67(4):335-41. PubMed ID: 10801241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors.
    Iribarne C; Berthou F; Carlhant D; Dreano Y; Picart D; Lohezic F; Riche C
    Drug Metab Dispos; 1998 Mar; 26(3):257-60. PubMed ID: 9492389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor.
    Zhang Y; Guo X; Lin ET; Benet LZ
    Drug Metab Dispos; 1998 Apr; 26(4):360-6. PubMed ID: 9531525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo effects of the arylamine human immunodeficiency virus protease inhibitor 4R-(4alpha,5alpha,6beta, 7beta)-1-[(3-(1-imidazoylcarbamoyl)phenyl)methyl]-3-[(3-aminophenyl)m ethyl]hexahydro-5,6-dihydroxy-4,7-bis(phenylmethyl)-2H-1, 3-diazepin-2-one (SD894) on rat hepatic cytochrome P450 2B and 3A.
    Grubb MF; Diamond S; Christ DD
    Drug Metab Dispos; 1997 Dec; 25(12):1424-8. PubMed ID: 9394033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism-based inactivation of CYP3A by HIV protease inhibitors.
    Ernest CS; Hall SD; Jones DR
    J Pharmacol Exp Ther; 2005 Feb; 312(2):583-91. PubMed ID: 15523003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxidation of 1,8-cineole, the monoterpene cyclic ether originated from eucalyptus polybractea, by cytochrome P450 3A enzymes in rat and human liver microsomes.
    Miyazawa M; Shindo M; Shimada T
    Drug Metab Dispos; 2001 Feb; 29(2):200-5. PubMed ID: 11159812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro metabolism of the HIV-1 protease inhibitor ABT-378: species comparison and metabolite identification.
    Kumar GN; Jayanti V; Lee RD; Whittern DN; Uchic J; Thomas S; Johnson P; Grabowski B; Sham H; Betebenner D; Kempf DJ; Denissen JF
    Drug Metab Dispos; 1999 Jan; 27(1):86-91. PubMed ID: 9884314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolism of 7-benzyloxy-4-trifluoromethyl-coumarin by human hepatic cytochrome P450 isoforms.
    Renwick AB; Surry D; Price RJ; Lake BG; Evans DC
    Xenobiotica; 2000 Oct; 30(10):955-69. PubMed ID: 11315104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation.
    Jones DR; Gorski JC; Hamman MA; Mayhew BS; Rider S; Hall SD
    J Pharmacol Exp Ther; 1999 Sep; 290(3):1116-25. PubMed ID: 10454485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of the human liver cytochrome P450 isoenzyme responsible for the 6-methylhydroxylation of the novel anticancer drug 5,6-dimethylxanthenone-4-acetic acid.
    Zhou S; Paxton JW; Tingle MD; Kestell P
    Drug Metab Dispos; 2000 Dec; 28(12):1449-56. PubMed ID: 11095582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of antidepressant drugs on the activity of cytochrome P-450 measured by caffeine oxidation in rat liver microsomes.
    Danie WA; Syrek M; Ryłko Z; Wójcikowski J
    Pol J Pharmacol; 2001; 53(4):351-7. PubMed ID: 11990081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s.
    Prueksaritanont T; Gorham LM; Ma B; Liu L; Yu X; Zhao JJ; Slaughter DE; Arison BH; Vyas KP
    Drug Metab Dispos; 1997 Oct; 25(10):1191-9. PubMed ID: 9321523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A.
    Niwa T; Shiraga T; Mitani Y; Terakawa M; Tokuma Y; Kagayama A
    Drug Metab Dispos; 2000 Sep; 28(9):1128-34. PubMed ID: 10950860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxidative metabolism of monensin in rat liver microsomes and interactions with tiamulin and other chemotherapeutic agents: evidence for the involvement of cytochrome P-450 3A subfamily.
    Nebbia C; Ceppa L; Dacasto M; Carletti M; Nachtmann C
    Drug Metab Dispos; 1999 Sep; 27(9):1039-44. PubMed ID: 10460804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions.
    Fabre G; Julian B; Saint-Aubert B; Joyeux H; Berger Y
    Drug Metab Dispos; 1993; 21(6):978-85. PubMed ID: 7905403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small intestinal metabolism of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor lovastatin and comparison with pravastatin.
    Jacobsen W; Kirchner G; Hallensleben K; Mancinelli L; Deters M; Hackbarth I; Baner K; Benet LZ; Sewing KF; Christians U
    J Pharmacol Exp Ther; 1999 Oct; 291(1):131-9. PubMed ID: 10490896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions.
    Fischer V; Johanson L; Heitz F; Tullman R; Graham E; Baldeck JP; Robinson WT
    Drug Metab Dispos; 1999 Mar; 27(3):410-6. PubMed ID: 10064574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.